(Q38248689)

1 September 2017

1 reference

title

Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches (English)

1 reference

1 September 2017

0 references

Ralf Reilmann

3

0 references

Cristina Sampaio

series ordinal

1

object named as

Cristina Sampaio

1 reference

1 September 2017

Beth Borowsky

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

29

1 reference

1 September 2017

issue

11

1 reference

1 September 2017

page(s)

1419-1428

1 reference

1 September 2017

1 reference

Pharmacologic approaches to the treatment of Huntington's disease

21 January 2018

1 reference

Huntington disease: natural history, biomarkers and prospects for therapeutics

21 January 2018

1 reference

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

The pridopidine paradox in Huntington's disease

21 January 2018

1 reference

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

21 January 2018

1 reference

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

21 January 2018

1 reference

Tapping linked to function and structure in premanifest and symptomatic Huntington disease

21 January 2018

1 reference

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

21 January 2018

1 reference

A 5-year follow-up of deep brain stimulation in Huntington's disease.

21 January 2018

1 reference

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.

21 January 2018

1 reference

Clinical development success rates for investigational drugs

21 January 2018

1 reference

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

21 January 2018

1 reference

Huntington's disease: effect of cysteamine, a somatostatin-depleting agent

21 January 2018

1 reference

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

21 January 2018

1 reference

Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.

21 January 2018

1 reference

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

21 January 2018

1 reference

Cysteamine: an old drug with new potential.

21 January 2018

1 reference

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease

21 January 2018

1 reference

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease

21 January 2018

1 reference

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study

21 January 2018

1 reference

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

Benefits, challenges and obstacles of adaptive clinical trial designs

21 January 2018

1 reference

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

21 January 2018

1 reference

Huntington disease: Clinical care and evaluation

21 January 2018

1 reference

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs

21 January 2018

1 reference

Unified Huntington's disease rating scale: a follow up.

21 January 2018

1 reference

Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures

21 January 2018

1 reference

Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease

21 January 2018

1 reference

Grasping premanifest Huntington's disease - shaping new endpoints for new trials

21 January 2018

1 reference

Cognitive domains that predict time to diagnosis in prodromal Huntington disease

21 January 2018

1 reference

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

21 January 2018

1 reference

HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.

21 January 2018

1 reference

An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers

21 January 2018

1 reference

Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease

21 January 2018

1 reference

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26021

1 reference

release_szxwvdwcdzd77ayixuihlklihe

1 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/szxwvdwcdzd77ayixuihlklihe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference